Royalty Pharma (RPRX) FCF Payout Ratio (QoQ) (2019 - 2026)
Royalty Pharma (RPRX) FCF Payout Ratio (QoQ) (2019 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
| 10 |
Royalty Pharma |
23.13 Bn |
25.57 Bn |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
-65.60% |
| Dec 31, 2025 |
429.78% |
| Sep 30, 2025 |
-224.29% |
| Jun 30, 2025 |
17.59% |
| Mar 31, 2025 |
-29.20% |
| Dec 31, 2024 |
302.25% |
| Sep 30, 2024 |
85.50% |
| Jun 30, 2024 |
-887.48% |
| Mar 31, 2024 |
151.88% |
| Dec 31, 2023 |
-141.94% |
| Sep 30, 2023 |
355.93% |
| Jun 30, 2023 |
-27.83% |
| Mar 31, 2023 |
-25.48% |
| Dec 31, 2022 |
308.75% |
| Sep 30, 2022 |
-152.52% |
| Jun 30, 2022 |
26.11% |
| Mar 31, 2022 |
110.37% |
| Dec 31, 2021 |
-399.59% |
| Sep 30, 2021 |
-145.19% |
| Jun 30, 2021 |
-94.13% |
